Since 1983 Dr Klein has spent much of his professional time developing drugs for the treatment of neurological and psychiatric conditions. At Burroughs Wellcome in Research Triangle Park, North Carolina he was Senior Medical Advisor and Assistant Director of the Department of Clinical Neurology. At Wellcome plc in London he was Principal Clinical Research Physician and Head of the Migraine Section of the Department of Clinical Neurology. He was Senior Clinical Programme Head of the Department of European CNS Clinical Research at GlaxoWellcome

While at Wellcome he was Global Project Leader for the anti-migraine drug zolmitriptan, now marketed as Zomig. In this position he led all aspects of the drug's worldwide development. This included primary responsibility for the design and implementation of the clinical trial program and coordination of the basic science, manufacturing, regulatory and commercial strategies.

Dr Klein has had extensive involvement in clinical research with a variety of antidepressants and antiepileptic agents. He has also helped develop drugs for acute pain, neuropathic pain, and other chronic pain syndromes. More than ten years prior to the development of Viagra, he lead the first pharmaceutical industry development program of a drug for the treatment of sexual dysfunction. He has given invited lectures on the design and conduct of treatment trials in migraine and in sexual dysfunction.

Following is a summary of some of the CNS-related areas in which he has direct drug development experience:

• migraine
  
• depression
  
• bipolar disorder
  
• epilepsy
  
• acute pain
  
• chronic pain
  
• sexual dysfunction
  
• Parkinson's disease
  
• schizophrenia
  
• neuromuscular blocking drugs